Results
1 -
9 of
9
(Click
here to explore results)
- New Tools to Interrogate Endocannabinoid Signalling: From Natural Compounds to Synthetic Drugs, Chapter 4 Natural Compounds and Synthetic Drugs to Target Type-2 Cannabinoid (CB2) Receptor. Wolfgang Guba, Marc Nazaré, Uwe Grether
, 2021
, Pages 89-167
- New Tools to Interrogate Endocannabinoid Signalling: From Natural Compounds to Synthetic Drugs, Chapter 3 Natural Compounds and Synthetic Drugs to Target Type-1 Cannabinoid (CB1) Receptor. Christos Iliopoulos-Tsoutsouvas, Markos-Orestis Georgiadis, Lipin Ji, Spyros P. Nikas, Alexandros Makriyannis
, 2021
, Pages 48-88
- Drug Discovery for Schizophrenia, CHAPTER 4 The Self-medication Hypothesis in Schizophrenia: What Have We Learned from Animal Models?. Bernard Le Foll, Enoch Ng, José M. Trigo, Patricia Di Ciano
, 2015
, Pages 70-88
- Anti-Inflammatory Drug Discovery, CHAPTER 13 Recent Advances in Selective CB2 Agonists for the Treatment of Pain. E. J. GILBERT, C. A. LUNN
, 2012
, Pages 391-413
- Pain Therapeutics: Current and Future Treatment Paradigms, CHAPTER 9 Affective and Cognitive Modulation of Pain. Weredeselam M. Olango, David P. Finn
, 2014
, Pages 269-308
- Forensic Chemistry of Substance Misuse: A Guide to Drug Control (2), CHAPTER 18 Synthetic Cannabinoid Receptor Agonists (SCRAs)
, 2022
, Pages 234-250
- New Tools to Interrogate Endocannabinoid Signalling: From Natural Compounds to Synthetic Drugs, Chapter 2 Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System. Javier Fernández-Ruiz, Onintza Sagredo, Eva de Lago
, 2021
, Pages 10-47
- New Tools to Interrogate Endocannabinoid Signalling: From Natural Compounds to Synthetic Drugs, Subject Index
, 2021
, Pages 451-457
- Drug Discovery for Schizophrenia, Subject Index
, 2015
, Pages 273-289